What is the best therapeutic approach to methicillin-resistant Staphylococcus aureus pneumonia?

Current Opinion in Infectious Diseases

Volumn 28, Issue 2, 2015, Pages 164-170

  Peyrani, Paula ^a   Ramirez, Julio ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Antibiotic treatment; Community acquired pneumonia; Hospital acquired pneumonia; Methicillin resistant Staphylococcus aureus; Pneumonia; Ventilator associated pneumonia

Indexed keywords

CEFTAROLINE; CEFTOBIPROLE; CLINDAMYCIN; GLYCOPEPTIDE; LINEZOLID; RIFAMPICIN; TEICOPLANIN; TELAVANCIN; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE STUDY; HUMAN; META ANALYSIS (TOPIC); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; NONHUMAN; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; VENTILATOR ASSOCIATED PNEUMONIA; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIOLOGY; PNEUMONIA, STAPHYLOCOCCAL; TREATMENT OUTCOME;

ACETAMIDES; ANTI-BACTERIAL AGENTS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; PNEUMONIA, STAPHYLOCOCCAL; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84926322984     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000149     Document Type: Review

References (28)

1. National Center for Health Statistics. National Vital Statistics Report. Deaths: Final Data for 2011. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr63/nvsr63-03.pdf. [Accessed 21 October 2014].
2. Frei CR, Attridge RT, Mortensen EM, et al. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit. Clin Therapeut 2010; 32:293-299.
3. Guidelines for the management of adults with hospital-acquired, ventilatorassociated, and healthcare-associated, pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
4. Holmes NE, Howden BP. What's new in the treatment of serious MRSA infection? Curr Opin Infect Dis 2014; 27:471-478.
5. Kalil AC, Klompas M, Haynatzki G, Rupp ME. Treatment of hospital-acquired pneumonia with linezolid or vancomycin: A systematic review and metaanalysis. BMJ Open 2013; 3:e003912.
6. Caffrey AR, Morrill HJ, Puzniak LA, Laplante KL. Comparative effectiveness of linezolid and vancomycin among a national veterans affairs cohort with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy 2014; 34:473-480.
7. Jiang H, Tang RN, Wang J. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials. Eur J Clin Microbiol Infect Dis 2013; 32:1121-1128.
8. Peyrani P, Wiemken TL, Kelley R, et al. Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: Results from the IMPACT-HAP study. Crit Care 2014; 18:R118.
9. Arshad S, Hartman P, Zervos MJ. A novel treatment option for MRSA pneumonia: Ceftaroline fosamil-yielding new hope in the fight against a persistent infection. Expert Rev Anti Infect Ther 2014; 12:727-729.
10. Casapao AM, Davis SL, Barr VO, et al. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother 2014; 58:2541-2546.
11. Pasquale TR, Tan MJ, Trienski TL, File TM Jr. Methicillin-resistant Staphylococcus aureus nosocomial pneumonia patients treated with ceftaroline: Retrospective case series of 10 patients. J Chemother 2015; 7:29-34.
12. AwadSS, RodriguezAH, ChuangYC, et al. APhase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis 2014; 59:51-61.
13. Barriere SL. The ATTAIN trials: Efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia. Future Microbiol 2014; 9:281-289.
14. Scott LJ. Telavancin: A review of its use in patients with nosocomial pneumonia. Drugs 2013; 73:1829-1839.
15. Torres A, Rubinstein E, Corey GR, et al. Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure. J Antimicrob Chemother 2014; 69:1119-1126.
16. Tremblay S, Lau TT, Ensom MH. Addition of rifampin to vancomycin for methicillin-resistant Staphylococcus aureus infections: what is the evidence? Ann Pharmacother 2013; 47:1045-1054.
17. Minejima E, Lou M, Nieberg P, Wong-Beringer A. Patients presenting to the hospital with MRSA pneumonia: Differentiating characteristics and outcomes with empiric treatment. BMC Infect Dis 2014; 14:252.
18. Wunderink RG. How important is methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia and what is best antimicrobial therapy? Infect Dis Clin North Am 2013; 27:177-188.
19. Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 8th ed. Elsevier; 2014.
20. Wunderink RG, Mendelson MH, Somero MS, et al. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest 2008; 134:1200-1207.
21. Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011; 52:31-40.
22. Corey GR, Kollef MH, Shorr AF, et al. Telavancin for hospital-acquired pneumonia: Clinical response and 28-day survival. Antimicrob Agents Chemother 2014; 58:2030-2037.
23. Carreno JJ, Lodise TP. Ceftaroline fosamil for the treatment of communityacquired pneumonia: from FOCUS to CAPTURE. Infect Dis Ther 2014; 3:123-132.
24. Udeani G, Evans J, Cole P, Friedland HD. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in elderly patients. Hosp Pract (1995) 2014; 42:109-115.
25. Syed YY. Ceftobiprole medocaril: A review of its use in patients with hospitalor community-acquired pneumonia. Drugs 2014; 74:1523-1542.
26. Nicholson SC, Welte T, File TM Jr, et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents 2012; 39:240-246.
27. Elisabeth P, Maria S, Irene G, et al. Success stories about severe pneumonia caused by Panton-Valentine leucocidin-producing Staphylococcus aureus. Br J Infect Dis: Off Publ Br Soc Infect Dis 2014; 18:341-345.
28. Melsen WG, Rovers MM, Groenwold RHH, et al. Attributable mortality of ventilator-associated pneumonia: A meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis 2013; 13:665-671.